Knowledge HQ

This abstract describes a streamlined protocol for manufacturing Monocyte-Derived Dendritic Cells (MoDC) using G-Rex devices. The method reduces cell loss associated with harvesting adherent cells and allows for the subsequent production of Tumor-Associated Antigen-Specific T Cells (TAAT) in the same vessel.

This study presents MARC, a modular CAR design that mimics native receptors to prevent tonic signaling and exhaustion. Primary T cells were transduced and expanded in 24-well G-Rex plates, demonstrating improved persistence and efficacy in leukemia models compared to traditional CARs.

This paper introduces Cas9-CLIPT, a method for efficient non-viral CRISPR-Cas9 knock-in of large transgenes (like CARs) into T cells. G-Rex 6M well plates were used for the expansion of CAR T cells during the manufacturing process, supporting clinical scalability.

This poster describes a simplified CAR-T manufacturing method (Spo-T) using RetroNectin-coated G-Rex vessels. This approach allows simultaneous T-cell activation and transduction in a single vessel, showing higher proliferation and stemness compared to conventional methods.

This study identifies PRDM1 as a key regulator of NKT cell central memory and effector function using CRISPR screening. PRDM1 knockdown preserved cytotoxicity and memory phenotype. NKT cells were expanded and restimulated in 6-well G-Rex plates during the protocol.

This study describes T cells engineered with five genes (WT1-TCR, NFAT-GMCAR, CD33 BiTE, tEGFR) to target AML. G-Rex plates were used for co-culture assays with primary AML cells and bone marrow to evaluate cytotoxicity and safety. The strategy enhances anti-tumor potency and provides a safety switch.

This study develops CD38KO/CD38-CAR γδT cells to treat T-cell malignancies, avoiding fratricide. A hybrid expansion protocol using G-Rex plates allowed robust expansion of polyclonal γδT cells. The edited cells showed potent anti-tumor activity in vitro and in vivo against T-ALL.

This study identifies CSF1R+ myeloid-monocytic (LAMM) cells as drivers of CAR-T resistance in B-NHL. CSF1R inhibition combined with CAR-T therapy enhanced efficacy. Author H. Balke-Want received funding from the G-Rex Grant Program (Wilson Wolf), though specific device usage for main data is not detailed.

This paper outlines a process for producing SRC-3 knockout human Tregs using CRISPR-Cas9. G-Rex devices were used to scale up production, achieving a 25-40 fold expansion in 14 days. The protocol is compatible with GMP standards for clinical-scale manufacturing of engineered Tregs.

This presentation details the process development (V2.0) for nula-cel, a gene-edited HSPC product for Sickle Cell Disease. G-Rex were implemented for cell culture, improving cell health and scalability compared to the V1.0 process. The optimized process showed improved engraftment and editing efficiency.

The study investigates the toxicity of CD147-CAR-NK therapy in a human CD147 transgenic mouse model. NK cells were expanded and transduced in G-Rex plates. Results indicate minimal on-target/off-tumor toxicities and less neuroinflammation compared to CAR-T therapy, supporting clinical potential.

This paper describes a knock-in strategy (KI-Ep) inserting a constitutive expression cassette into the CX3CR1 locus of HSPCs to regulate transgene expression. G-Rex systems were used for the long-term culture of edited HSPCs. The method enables low expression in stem cells and activation upon myeloid differentiation.